Overview

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Vaccines